(CercleFinance.com) – Valneva announces the sale for 103 million dollars (95 million euros) of the priority review voucher that it obtained from the American FDA, for its single injection vaccine for the prevention of the disease caused by the chikungunya virus.
The company received this voucher in November 2023 with marketing authorization. With this US authorization, Ixchiq became the first vaccine in the world to be authorized against chikungunya, an unmet medical need.
Valneva will use the proceeds from the sale of the voucher to finance its R&D projects, including the co-development of its Lyme disease vaccine currently in phase III and the launch of additional clinical trials for Ixchiq.